Does filgotinib belong to the class of selective JAK inhibitors?

Filgotinib(Filgotinib) is an oral small molecule drug. Its main mechanism of action is to selectively inhibit JAK1 in the Janus kinase (JAK) family. JAK inhibitors are a type of targeted therapy drugs that have attracted much attention in recent years and are mainly used in a variety of autoimmune diseases, such asrheumatoid arthritis, ulcerative colitis, etc. The JAK signaling pathway plays a key role in a variety of immune responses and inflammatory responses, affecting the activity of the immune system by regulating the transduction process of cytokines.

Figotinib has higher JAK1 selectivity than other broad-spectrum JAK inhibitors such as Tofacitinib (JAK1/3 inhibitor) or Baricitinib (JAK1/2 inhibitor). This feature makes it possible to reduce the impact on other physiological pathways while inhibiting the inflammatory response, thereby reducing the risk of side effects. Because of its high selectivity for JAK1, filgotinib is classified as a "selective JAK inhibitor" and is currently a new first-line option in the treatment of rheumatoid arthritis in many European and American countries.

From a scientific mechanism perspective,JAK1 is involved in the signal transduction of inflammatory factors including IL-6, IFN and other factors. Inhibiting JAK1 can effectively block the chronic inflammatory response caused by these factors. The original intention of the development of filgotinib was to control inflammation while trying to avoid the risk of immunosuppression and infection caused by broad-spectrum inhibition of the JAK pathway. Therefore, filgotinib has shown good tolerability and therapeutic effect in multiple overseas clinical studies, especially in rheumatoid arthritis, and has been approved by the EMA (European Medicines Agency) and Japan's PMDA.

In summary, filgotinib is indeed a selective JAK inhibitor. Its pharmacological mechanism and clinical performance support its use as a precisely targeted anti-inflammatory treatment. With the continuous advancement of precision medicine worldwide, filgotinib, a new generation of JAK1 selective inhibitor, is expected to play an increasingly important role in the treatment of autoimmune diseases.

Reference materials:https://go.drugbank.com/drugs/DB14845